Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of topical RV3131A-HC3221 in prevention of polymorphic light eruption
2004-001241-14Phase 2Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of RV3131A-HC3221 in polymorphic light eruption (PMLE), sponsored by Pierre Fabre Laboratories. Primary endpoint: Preventive activity against PMLE on treated areas. Started Oct 2004; status: completed.
02
Drugs
RV3131A-HC3221
03
Conditions
polymorphic light eruption (PMLE)
Beyond the preview
Go deeper on 2004-001241-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001241-14.